查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1718074

改質細胞培養補充劑市場（按產品類型、來源、應用和最終用戶）—2025 年至 2030 年全球預測

Recombinant Cell Culture Supplements Market by Product Type, Source, Application, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年基因改造細胞培養補充劑市值為 9.5689 億美元，預計 2025 年將成長至 10.7976 億美元，複合年成長率為 13.13%，預計到 2030 年將達到 20.0706 億美元。

主要市場統計數據
基準年2024年 9.5689億美元
預計2025年 10.7976億美元
預測年份 2030 20.706億美元
複合年成長率（%） 13.13%

在當今快速發展的生物製藥環境中，重組細胞培養補充劑已成為現代生物技術和治療方法發展的基石。隨著科技創新、生產技術的改進以及法規的嚴格推動研究和商業性應用，市場正在經歷重大變革。重組補充劑現在對於支持細胞生長和確保一致的生產品質至關重要，從而加速再生醫學、基因治療和疫苗開發的關鍵突破。該報告對市場動態進行了深入研究，重點關注影響市場力量的技術進步和新興行業趨勢。

研究和行業領導者都認知到，重組補充劑不僅比傳統的動物和人類衍生替代品具有更高的安全性和性能，而且還為提高製造過程的效率和永續性鋪平了道路。這裡提供的分析有全面的數據和深刻的說明作為支持，是策略決策者的寶貴資源。透過深入研究市場區隔、區域趨勢和主要產業參與企業，本執行摘要為了解重組細胞培養補充劑的現狀和未來前景奠定了基礎。

重新定義重組細胞培養補充劑市場的變革性轉變

重組細胞培養補充劑市場正在經歷重塑其整體情況的變化。近年來，生物加工技術的突破以及基因工程的進步使得補充劑生產方法從傳統的方法轉向重組方法。這些發展帶來了一致、可擴展的產品，這對於滿足全球對高品質生物製藥產品日益成長的需求至關重要。

競爭領域的一個顯著變化是更加重視永續性和道德製造實踐。隨著監管機構執行更嚴格的指導方針和行業標準，公司被迫在確保合規的同時不斷創新。這種變化也體現在研發投入的增加，從而導致技術改進，提高了產品純度並降低了生產成本。此外，不斷變化的市場需求正在鼓勵跨領域的合作，並推動實驗研究和工業製造的整合。這些發展使得經營模式能夠更好地響應患者需求和技術期望的變化。

因此，目前的市場環境以強勁的創新為特徵，精度、品質和效率不再是可有可無的，而是企業保持競爭力的必要條件。

推動市場動態的關鍵細分洞察

對重組細胞培養補充劑市場的全面細分揭示了影響當前策略和未來方向的多層關鍵見解。按產品類型進行分析考慮了各種產品，例如重組白蛋白、重組抑肽酶、重組生長因子、重組胰島素、重組轉鐵蛋白、重組胰蛋白酶等。這些變體在促進細胞培養過程和確保最佳產品性能方面發揮著獨特但相互關聯的作用。

從動物和人類衍生這兩個角度檢驗市場，突顯了隨著行業趨勢日益轉向與人類相容的材料，向安全和道德考慮的轉變。另一層市場細分著重於應用，市場格局涵蓋生物製藥生產、基因治療、幹細胞治療和組織工程。在生物製藥製造領域，單株抗體、重組蛋白和疫苗等專業研究領域凸顯了基於應用的需求的多樣性和複雜性。

此外，考慮到最終用戶，該市場迎合了學術研究機構、契約製造組織以及製藥和生物製藥公司。這種多方面的細分策略將使相關人員能夠根據每個細分市場和應用細分市場的細微需求來客製化自己的方法、投資和創新。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 在研究和生產過程中擴大採用無動物成分的細胞培養補充劑
      • 疫苗生產需要永續的重組細胞培養替代品
      • 生物製藥和生物相似藥需求成長推動工程細胞培養補充劑
    • 限制因素
      • 對產品功效的擔憂影響了改良細胞培養補充劑的需求
    • 機會
      • 幹細胞治療研究活動的增加為新的細胞培養補充劑創造了機會
      • 個人化醫療日益成長的興趣推動了高效的工程細胞培養補充劑
    • 任務
      • 供應鏈中斷及其對基因改造細胞培養補充劑可用性和品質的影響
  • 市場區隔分析
    • 產品類型：重組白蛋白在疫苗和治療性蛋白質生產的應用日益增多
    • 最終用戶：擴大學術研究機構重組細胞培養補充品的研發活動
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 基因改造細胞培養補充劑市場（依產品類型）

  • 介紹
  • 重組白蛋白
  • 重組抑肽酶
  • 重組生長因子
  • 重組胰島素
  • 重組轉鐵蛋白
  • 重組胰蛋白酶

7. 基因改造細胞培養補充劑市場（按來源）

  • 介紹
  • 動物源性補充劑
  • 人體來源的補充劑

8. 基因改造細胞培養補充劑市場（按應用）

  • 介紹
  • 生物製藥製造
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 基因治療
  • 幹細胞療法
  • 組織工程

9. 基因改造細胞培養補充劑市場（按最終用戶）

  • 介紹
  • 學術研究所
  • 契約製造組織
  • 製藥和生物製藥公司

10. 美洲改良細胞培養補充品市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區改良細胞培養補充品市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲改良細胞培養補充品市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abcam Limited
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Biocon Limited
  • BPS Bioscience, Inc.
  • Cell Sciences, Inc.
  • Corning Incorporated
  • Cytiva
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Corporation
  • HiMedia Laboratories Pvt Ltd
  • InVitria
  • Kingfisher BIoTech, Inc.
  • Laurus Labs Limited
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi BIoTec BV & Co. KG
  • Novo Nordisk A/S
  • Novozymes A/S
  • PELOBIOTECH GmbH
  • Repligen Corporation
  • Sartorius AG
  • STEMCELL Technologies
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Zhuhai Gene-Biocon Biological Technology Co., Ltd.
Product Code: MRR-5C6F41F5B035

The Recombinant Cell Culture Supplements Market was valued at USD 956.89 million in 2024 and is projected to grow to USD 1,079.76 million in 2025, with a CAGR of 13.13%, reaching USD 2,007.06 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 956.89 million
Estimated Year [2025] USD 1,079.76 million
Forecast Year [2030] USD 2,007.06 million
CAGR (%) 13.13%

In today's rapidly advancing biopharmaceutical environment, recombinant cell culture supplements have become a cornerstone in modern biotechnology and therapeutic development. The market is experiencing significant evolution as scientific innovations, improved production techniques, and heightened regulatory frameworks drive research and commercial applications. Recombinant supplements are now integral in supporting cell growth and ensuring consistent production quality, which in turn accelerates critical breakthroughs in regenerative medicine, gene therapy, and vaccine development. This report offers a detailed exploration into the market dynamics, highlighting both the technological strides and emerging industry trends that influence market forces.

Researchers and industry leaders alike recognize that recombinant supplements not only offer improved safety and performance over conventional animal- or human-derived alternatives but also pave the way for enhanced efficiency and sustainability in manufacturing processes. The analysis provided herein is backed by comprehensive data and insightful commentary, making it a valuable resource for strategic decision-makers. By delving into market segmentation, regional trends, and key industry players, this executive summary lays the foundation for understanding both current conditions and future prospects within recombinant cell culture supplements.

Transformative Shifts Redefining the Recombinant Cell Culture Supplements Market

The recombinant cell culture supplements market has witnessed transformative shifts that are reshaping its overall landscape. In recent years, breakthroughs in bioprocessing, coupled with advancements in genetic engineering, have enabled a move from traditional supplement production methods to approaches that harness recombinant technologies. These developments have resulted in superior product consistency and scalability, which are essential for meeting the rising global demand for high-quality biopharmaceutical products.

A notable change in the competitive arena is the increasing focus on sustainability and ethical manufacturing practices. As regulatory authorities enforce stricter guidelines and industry standards, companies are compelled to innovate continuously while ensuring compliance. This shift is also reflected in increased investments in research and development, leading to the refinement of techniques that enhance product purity and reduce production costs. Moreover, evolving market needs have prompted cross-disciplinary collaboration, driving integration between experimental research and industrial production. Such developments have allowed for adaptive business models that are more responsive to fluctuations in patient needs and technological expectations.

Consequently, the current market environment is marked by robust innovation where precision, quality, and efficiency are no longer optional but vital imperatives for companies striving to maintain a competitive edge.

Key Segmentation Insights Driving Market Dynamics

A comprehensive segmentation of the recombinant cell culture supplements market reveals layers of critical insights that are shaping both current strategies and future directions. Analysis based on product type examines a spectrum of offerings, including recombinant albumin, recombinant aprotinin, recombinant growth factors, recombinant insulin, recombinant transferrin, and recombinant trypsin. These variants serve distinct yet interconnected roles in facilitating cell culture processes and ensuring optimum product performance.

Examining the market through the lens of source has provided a dichotomy between animal-derived and human-derived supplements, highlighting shifts toward safety and ethical considerations as industry trends lean increasingly towards human-compatible materials. An additional layer of segmentation focuses on application, where the market landscape spans biopharmaceutical production, gene therapy, stem cell therapy, and tissue engineering. Within biopharmaceutical production, specialized study segments-monoclonal antibodies, recombinant proteins, and vaccines-underscore the diversity and complexity of application-based demand.

Moreover, when considering end-users, the market caters to academic and research institutes, contract manufacturing organizations, and pharmaceutical as well as biopharmaceutical companies. This multifaceted segmentation strategy enables stakeholders to tailor their approach, ensuring that investments and innovations align with the nuanced needs of each segment and application area.

Based on Product Type, market is studied across Recombinant Albumin, Recombinant Aprotinin, Recombinant Growth Factors, Recombinant Insulin, Recombinant Transferrin, and Recombinant Trypsin.

Based on Source, market is studied across Animal-derived Supplements and Human-derived Supplements.

Based on Application, market is studied across Biopharmaceutical Production, Gene Therapy, Stem Cell Therapy, and Tissue Engineering. The Biopharmaceutical Production is further studied across Monoclonal Antibodies, Recombinant Proteins, and Vaccines.

Based on End-Users, market is studied across Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies.

Global Regional Analysis in Recombinant Cell Culture Supplements

The global reach of recombinant cell culture supplements makes regional analysis a critical component of the market overview. The Americas have emerged as a vibrant hub for research and development, driven by well-established infrastructure and significant funding dedicated to biotechnology. This region is characterized by an impressive network of academic institutions and innovative private sector ventures that collectively drive market growth.

Europe, Middle East & Africa present a diverse set of opportunities where a balanced mix of regulatory rigor and investment in emerging technologies has fostered a robust market environment. Countries within this cluster are uniquely positioned to leverage historical expertise with current advances in cell culture supplements, ensuring that innovations translate effectively into practical applications.

Asia-Pacific continues to reveal rapid expansion driven by both technological adoption and cost-effective manufacturing capabilities. The region's dynamic economic landscape, coupled with a focus on scalability and operational efficiency, is contributing significantly to the global market share while propelling future growth prospects. This regional insight underscores the varied yet interconnected nature of market development across continents, reflecting a global tapestry of technological progress and market evolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Industry Leaders Shaping the Supplement Innovation

The recombinant cell culture supplements arena is enriched by contributions from globally recognized industry leaders whose innovative portfolio continues to redefine market parameters. Esteemed companies such as Abcam Limited, Becton, Dickinson and Company, and Bio-Techne Corporation have been at the forefront in advancing product development. Other notable entities including Biocon Limited, BPS Bioscience, Inc., Cell Sciences, Inc., and Corning Incorporated have consistently provided robust solutions that address the technical challenges associated with cell culture and bioprocessing.

Key players like Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, and HiMedia Laboratories Pvt Ltd add to the vibrant competitive landscape, supported by pioneering research and significant investments in technology. Furthermore, organizations including InVitria, Kingfisher Biotech, Inc., Laurus Labs Limited, and Lonza Group Ltd. continue to fuel progress through strategic partnerships and R&D collaborations. The impressive list is further bolstered by Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novo Nordisk A/S, and Novozymes A/S, among others, all of which contribute unique strengths and market insights.

These key companies not only drive innovations within the field but also foster an environment where continued excellence in research and product quality reinforces the overall market trajectory. Their collective efforts are instrumental in setting benchmarks and encouraging industry-wide best practices that resonate across the global biopharmaceutical landscape.

The report delves into recent significant developments in the Recombinant Cell Culture Supplements Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited, Becton, Dickinson and Company, Bio-Techne Corporation, Biocon Limited, BPS Bioscience, Inc., Cell Sciences, Inc., Corning Incorporated, Cytiva, F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, HiMedia Laboratories Pvt Ltd, InVitria, Kingfisher Biotech, Inc., Laurus Labs Limited, Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novo Nordisk A/S, Novozymes A/S, PELOBIOTECH GmbH, Repligen Corporation, Sartorius AG, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., and Zhuhai Gene-Biocon Biological Technology Co., Ltd.. Guidance for Strategic Leadership in the Recombinant Supplement Sector

For industry leaders aiming to capitalize on the potential of recombinant cell culture supplements, adopting a multi-pronged strategic approach is essential. Firstly, it is crucial to foster investment in advanced research and development that centers on enhancing the purity and consistency of recombinant products. This includes leveraging state-of-the-art technologies and integrating robust quality control measures into every phase of product development and manufacturing.

Secondly, companies should prioritize the expansion of their market presence by tapping into emerging regional opportunities. A strategic focus on regions like Asia-Pacific, along with sustained engagement in Americas and Europe, Middle East & Africa, can result in diversified revenue streams and favorable market positioning. Collaborations between multinational entities and local regulatory bodies are also necessary to refine product offerings in accordance with regional standards and consumer expectations.

Thirdly, refining segmentation strategies can empower businesses to tailor solutions that effectively meet diverse end-user needs. By harnessing data-driven insights that consider variations in product type, source, application, and end-user profiles, decision-makers can develop more targeted and innovative product lines. Finally, leaders must remain agile and responsive to regulatory changes and technological advancements, ensuring that strategic pivots are well-aligned with the evolving market landscape.

Conclusion: Charting a Future of Sustainable Growth

In summary, the recombinant cell culture supplements market is positioned at the intersection of cutting-edge technology and dynamic global trends. The analysis presented herein demonstrates that evolving methodologies, strategic segmentation, and the unparalleled contributions of industry leaders are collectively propelling the market toward unprecedented growth. The integration of advanced biotechnology into supplement production not only addresses current challenges but also paves the way for innovations that will transform therapeutic development across various applications.

This comprehensive overview underscores that a nuanced understanding of market segmentation-ranging from product type to source, application, and end-user demographics-is essential for navigating the complexities of this sector. Furthermore, regional insights provide a holistic view of how local innovations and market dynamics can drive global trends. The synthesis of these insights reassures stakeholders that sound investments in research and infrastructure, along with strategic agility, will be instrumental in maintaining momentum in a rapidly evolving marketplace.

Embracing these strategic imperatives will ensure that the market continues to thrive, setting a course for sustainable growth and long-term success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of animal-free cell culture supplements in research and production processes
      • 5.1.1.2. Needs in vaccine production with sustainable recombinant cell culture alternatives
      • 5.1.1.3. Rising demand for biologics and biosimilars boosting recombinant cell culture supplements
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns surrounding product efficacy affecting demand for recombinant cell culture supplements
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities in stem cell therapy creating opportunities for novel cell culture supplements
      • 5.1.3.2. Growing interest in personalized medicine boosts efficient recombinant cell culture supplements
    • 5.1.4. Challenges
      • 5.1.4.1. Supply chain disruptions and their effect on availability and quality of recombinant cell culture supplements
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing utilization of recombinant albumin for the production of vaccines and therapeutic proteins
    • 5.2.2. End-Users: Expanding research & development activities for recombinant cell culture supplements in academic and research institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Recombinant Cell Culture Supplements Market, by Product Type

  • 6.1. Introduction
  • 6.2. Recombinant Albumin
  • 6.3. Recombinant Aprotinin
  • 6.4. Recombinant Growth Factors
  • 6.5. Recombinant Insulin
  • 6.6. Recombinant Transferrin
  • 6.7. Recombinant Trypsin

7. Recombinant Cell Culture Supplements Market, by Source

  • 7.1. Introduction
  • 7.2. Animal-derived Supplements
  • 7.3. Human-derived Supplements

8. Recombinant Cell Culture Supplements Market, by Application

  • 8.1. Introduction
  • 8.2. Biopharmaceutical Production
    • 8.2.1. Monoclonal Antibodies
    • 8.2.2. Recombinant Proteins
    • 8.2.3. Vaccines
  • 8.3. Gene Therapy
  • 8.4. Stem Cell Therapy
  • 8.5. Tissue Engineering

9. Recombinant Cell Culture Supplements Market, by End-Users

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Manufacturing Organizations
  • 9.4. Pharmaceutical & Biopharmaceutical Companies

10. Americas Recombinant Cell Culture Supplements Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Cell Culture Supplements Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Cell Culture Supplements Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Croda Pharma's innovative solution enhances cell culture performance with Super Refined Poloxamer 188 launch
    • 13.3.2. Axio BioPharma expands with new protein manufacturing services in Madison to meet biopharma demand
    • 13.3.3. Core Biogenesis and Nucleus Biologics announce strategic collaboration for manufacturing and distribution of cost effective and sustainable recombinant proteins
    • 13.3.4. Strategic partnership between Nucleus Biologics and Core Biogenesis to revolutionize sustainable cell culture media with plant-based recombinant proteins
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam Limited
  • 2. Becton, Dickinson and Company
  • 3. Bio-Techne Corporation
  • 4. Biocon Limited
  • 5. BPS Bioscience, Inc.
  • 6. Cell Sciences, Inc.
  • 7. Corning Incorporated
  • 8. Cytiva
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. FUJIFILM Corporation
  • 11. HiMedia Laboratories Pvt Ltd
  • 12. InVitria
  • 13. Kingfisher Biotech, Inc.
  • 14. Laurus Labs Limited
  • 15. Lonza Group Ltd.
  • 16. Merck KGaA
  • 17. Miltenyi Biotec B.V. & Co. KG
  • 18. Novo Nordisk A/S
  • 19. Novozymes A/S
  • 20. PELOBIOTECH GmbH
  • 21. Repligen Corporation
  • 22. Sartorius AG
  • 23. STEMCELL Technologies
  • 24. Takara Bio Inc.
  • 25. Thermo Fisher Scientific Inc.
  • 26. Zhuhai Gene-Biocon Biological Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET MULTI-CURRENCY
  • FIGURE 2. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET MULTI-LANGUAGE
  • FIGURE 3. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET RESEARCH PROCESS
  • FIGURE 4. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT APROTININ, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT TRANSFERRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT TRYPSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY ANIMAL-DERIVED SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY HUMAN-DERIVED SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 239. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 240. RECOMBINANT CELL CULTURE SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024